Cellebrite DI Ltd. $CLBT Stock Position Increased by Wealth Enhancement Advisory Services LLC

Key Points

• Wealth Enhancement Advisory Services LLC significantly increased its position in Cellebrite DI Ltd. by 1,749.9% in the second quarter, holding approximately 256,196 shares valued at around $3.96 million.
• Cellebrite DI Ltd. reported an earnings per share (EPS) of $0.12 for the last quarter, exceeding analysts' expectations of $0.11, with revenue growing 18.4% year-over-year.
• Recent analyst ratings have shown mixed sentiments, with several firms adjusting their price targets; Needham reduced its target from $24 to $18, while JPMorgan lifted it from $20 to $23.

Wealth Enhancement Advisory Services LLC raised its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 1,749.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 256,196 shares of the company's stock after purchasing an additional 242,347 shares during the quarter. Wealth Enhancement Advisory Services LLC owned about 0.11% of Cellebrite DI worth $3,958,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in CLBT. Assetmark Inc. bought a new stake in Cellebrite DI during the 1st quarter valued at $33,000. Catalyst Capital Advisors LLC bought a new stake in shares of Cellebrite DI during the first quarter valued at about $51,000. Virtus Advisers LLC acquired a new stake in Cellebrite DI in the first quarter worth about $63,000. Advisors Asset Management Inc. grew its position in Cellebrite DI by 24.7% in the 1st quarter. Advisors Asset Management Inc. now owns 6,133 shares of the company's stock valued at $119,000 after buying an additional 1,214 shares in the last quarter. Finally, JT Stratford LLC acquired a new position in Cellebrite DI during the 1st quarter valued at about $209,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Stock Performance

NASDAQ CLBT opened at $18.30 on Friday. Cellebrite DI Ltd. has a 1 year low of $13.10 and a 1 year high of $26.30. The business's fifty day moving average is $15.73 and its two-hundred day moving average is $16.95. The stock has a market capitalization of $4.38 billion, a P/E ratio of -24.08, a P/E/G ratio of 3.35 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The business had revenue of $113.28 million for the quarter, compared to analysts' expectations of $112.33 million. During the same period in the previous year, the firm posted $0.10 EPS. The company's quarterly revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Cellebrite DI from a "buy" rating to a "hold" rating in a research note on Saturday, September 13th. Needham & Company LLC cut their target price on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. JPMorgan Chase & Co. increased their price target on Cellebrite DI from $20.00 to $23.00 and gave the company an "overweight" rating in a research note on Wednesday. Finally, Lake Street Capital dropped their price objective on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $21.75.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.